How do patient and hospital features influence outcomes in small-cell lung cancer in England

British Journal of Cancer

Volumn 105, Issue 6, 2011, Pages 746-752

  Rich, A L ^a   Tata, L J ^a   Free, C M ^b   Stanley, R A ^c   Peake, M D ^b   Baldwin, D R ^d   Hubbard, R B ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

chemotherapy; epidemiology; small cell lung cancer; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMORBIDITY; FEMALE; HEALTH CARE ACCESS; HOSPITAL CARE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMORBIDITY; ENGLAND; FEMALE; HEALTH SERVICES ACCESSIBILITY; HOSPITALS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS;

EID: 80052457148     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.310     Document Type: Article

References (30)

1. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham G B Goss CD (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26(1): 54-59
2. Brown JS, Eraut D, Trask C, Davison AG. (1996) Age and the treatment of lung cancer. Thorax 51(6): 564-568 (Pubitemid 26226507)
3. Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J (2000) Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer 82(11): 1863-1866 (Pubitemid 30307401)
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373-383 (Pubitemid 17055592)
5. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 52(12): 1131-1136 (Pubitemid 29535412)
6. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760): 127-138
7. Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP (2009) Social and geographical factors affecting access to treatment of lung cancer. Br J Cancer 101(6): 897-901
8. Department of Health (1995) A Policy Framework for Commissioning Cancer Services: A Report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales
9. Department of Health (1998) Guidance on Commissioning Cancer Services; Improving Outcomes in Lung Cancer: The Manual
10. Department of Health (2000) The NHS Cancer Plan
11. Department of Health (2007) Cancer Reform Strategy
12. Jack RH, Gulliford MC, Ferguson J, Moller H. (2003) Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services? Br J Cancer 88(7): 1025-1031 (Pubitemid 36560769)
13. Jack RH, Gulliford MC, Ferguson J, Moller H (2006) Explaining inequalities in access to treatment in lung cancer. J Eval Clin Pract 12(5): 573-582 (Pubitemid 44427290)
14. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW (1998) Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21(2): 105-113 (Pubitemid 29028028)
15. Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D (2008) Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 44(7): 992-999
16. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11: 1
17. Li J, Chen P, Dai CH, Li XQ, Bao QL (2009) Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study. Geriatr Gerontol Int 9(2): 172-182
18. Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, Martins H, Lim J (2003) Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 55(5): 1321-1330 (Pubitemid 36338300)
19. National Institute for Clinical Excellence (2005) The Diagnosis and Treatment of Lung Cancer
20. National Lung Cancer Audit (2008) Key findings about the quality of care for people with lung cancer in England and Wales incorporating headline and completeness data from Scotland. Report for the Audit Period 2007. The NHS Information Centre for Health and Social Care
21. National Lung Cancer Audit (2009) Annual Report
22. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Osterlind K, Tatersall MHN, Wagner H (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23): 1618-1624
23. Rich AL, Tata LJ, Free CM, Stanley RA, Peake MP, Baldwin DR, Hubbard RB (2011a) Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service. Thorax; e-pub ahead of print 23 July 2011, doi:10.1136/thx.2011.158972
24. Rich AL, Tata LJ, Stanley RA, Free CM, Peake MD, Baldwin DR, Hubbard RB. (2011b) Lung cancer in England: information from the National Lung Cancer Audit (LUCADA). Lung Cancer 72(1): 16-22
25. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44(8): 631-633 (Pubitemid 19197232)
26. Stiller CA. (1994) Centralised treatment, entry to trials and survival. Br J Cancer 70(2): 352-362 (Pubitemid 24247163)
27. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8(9): 784-796 (Pubitemid 47321601)
28. Wang CY, Lin YS, Tzao C, Lee HC, Huang MH, Hsu WH, Hsu HS. (2007) Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 32(6): 877-881 (Pubitemid 350064558)
29. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10(6): 890-895
30. Yau T, Ashley S, Popat S, Norton A, Matakidou A, Coward M, O'Brien JE (2006) Time and chemotherapy treatment trends in the treatment of elderly patients (age 4/70 years) with small cell lung cancer. Br J Cancer 94(1): 18-21 (Pubitemid 43088535)